Clinical Trials Browser

Phase 3 × Has results × relugolix × Clear all

NCT03751124 2024-06-25

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3 Completed

229 enrolled 66 charts

Leiomyoma, Menorrhagia, Myofibroma

NCT03412890 2024-05-09

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3 Completed

477 enrolled 27 charts

Leiomyoma, Menorrhagia

NCT03103087 2022-04-20

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3 Completed

382 enrolled 57 charts

Leiomyoma, Menorrhagia

NCT03049735 2022-04-19

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3 Completed

388 enrolled 54 charts

Leiomyoma, Menorrhagia

NCT03085095 2022-01-18

HERO

Phase 3 Completed

1,134 enrolled 38 charts 1 FDA

Prostatic Neoplasms

NCT02655224 2019-03-22

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Phase 3 Completed

65 enrolled 28 charts

Leiomyoma

NCT02655237 2019-03-22

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Phase 3 Completed

281 enrolled 37 charts

Leiomyoma